Lexicon Announces Proposed Public Offering of Common Stock

Core Viewpoint - Lexicon Pharmaceuticals, Inc. has initiated an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option for additional shares, subject to market conditions [1][2] Group 1: Offering Details - The public offering will include shares of common stock with a par value of $0.001, and the actual size and terms of the offering are not guaranteed [1] - Jefferies and Piper Sandler are serving as joint book-running managers for the offering [2] - Concurrently, Lexicon plans to conduct a private placement of common stock to Invus, L.P., its largest stockholder, which will not be registered under the Securities Act [3] Group 2: Use of Proceeds - Lexicon intends to utilize the net proceeds from the offering primarily for the research and development of its drug candidates, as well as for working capital and general corporate purposes [4] Group 3: Regulatory Information - A shelf registration statement related to the offering was filed with the SEC on August 2, 2024, and was declared effective on August 15, 2024 [5]